1. Teva receives a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. 2. Their drug pipeline is robust and diverse, including cancer drugs, and existing drugs on the market across multiple clinical segments. 3. Despite high debt to equity compared to peers, debt is on a declining trend. 4. A key risk in the pharmaceutical space is facing costly legal/regulatory cases.